Sundén M, et al. - Survival after isolated breast cancer liver metastases (BCLM) was investigated in nationwide cohorts. Further, surgical vs systemic treatment regimens were compared. Researchers queried the Swedish register for cancer in the liver and the bile ducts and the National Register for breast cancer and identified a surgical cohort (n = 29) and a control cohort (n = 33) receiving systemic treatment only. Outcomes support the safety of performing surgery for BCLM; it might afford a survival benefit in selected patients. No 90-day mortality was reported after surgery. In the surgical cohort, median survival from BCLM diagnosis was 77 months (95% CI 41-113) vs 28 months (95% CI 13-43) in the control cohort.